Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review

Executive Summary

FDA's Oncologic Drugs Advisory Committee recommends 10-0 the agency approve Novartis' tisagenlecleucel (CTL019) for pediatric leukemia in a panel review that was hailed by some in the industry as historic.

Advertisement

Related Content

Rising Tide Lifts All CAR-T Ships After Gilead/Kite Deal, Kymriah Approval
Novartis CAR-T Therapy's Swift Approval Aided By REMS And New US FDA Review Model
What's Next On Gilead's Shopping List
Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy
What's Gilead Getting From Kite For Nearly $12bn?
Trial And Trial: Bracing For Commercialization Of Cell & Gene Therapies
Novartis' CAR-T Therapy Faces Quality, Safety Concerns At FDA Advisory Panel
Novartis' CAR-T CTL019 Back On The Blockbuster Hit List
Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position
A New Industry-Academic Model: Novartis And Penn Make A Splash In Cancer Immunotherapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel